Increased sMICA and TGFβ1levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells

Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention

(2014) Aroa Baragaño Raneros et al.   OncoImmunology

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17

(2013) Guranda Chitadze et al.   INTERNATIONAL JOURNAL OF CANCER

New prospects on the NKG2D/NKG2DL system for oncology

(2013) Evelyn Ullrich et al.   OncoImmunology

Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol

(2013) Ulrike Koehl et al.   Frontiers in Oncology

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Immune Suppression in Head and Neck Cancers: A Review

(2011) Anaëlle Duray et al.   Clinical & Developmental Immunology

Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression

(2011) Lucas E. Rossi et al.   JOURNAL OF LEUKOCYTE BIOLOGY

TGF-  downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

(2011) C. A. Crane et al.   NEURO-ONCOLOGY

Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity

(2011) Erica B. Wilson et al.   PLoS One

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA

(2010) Stephan Kloess et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer

(2010) Claire McLarnon et al.   Expert Review of Anticancer Therapy

IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion

(2010) Sabine Huenecke et al.   JOURNAL OF IMMUNOTHERAPY

Soluble HLA-I-mediated secretion of TGF-β1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity

(2009) Massimo Ghio et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The Soluble   Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer

(2008) C. Badoual et al.   CANCER RESEARCH

Relationship between soluble MICA and the MICA A5.1 homozygous genotype in patients with oral squamous cell carcinoma

(2008) Shigehiro Tamaki et al.   CLINICAL IMMUNOLOGY

Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis

(2008) Sabine Huenecke et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Tumor cell recognition by the NK cell activating receptor NKG2D

(2008) Yenan T. Bryceson et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients

(2008) Shigehiro Tamaki et al.   HUMAN IMMUNOLOGY